MedTrace Logo

Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients

NCT00804349 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-03-09

Study results available
· View outcomes & findings →

Summary

Heart Failure affects 5-6 million Americans and there are about 550 thousand new cases of heart failure every year. There are approximately 3 million hospital admission for acute decompensated heart failure with hospital readmission rate of 20% at 30 days and 50% at 60 day, costing up to 20 billion dollars per year. In our previous study we have discovered that sleep disordered breathing is prevalent in 70% of patients with acute decompensated heart failure. We hypothesize that, detection and treatment of sleep disordered breathing in acute decompensated heart failure patients will reduce episodic hypoxic events during acute decompensation and may decrease hospital length of stay and reduce future readmissions.

Conditions

Interventions

DEVICE

Autotitrating Positive Airway Pressure

Patients will be treated with Autotitrating Positive Airway Pressure therapy

Sponsors & Collaborators

  • Nexan Inc

    collaborator INDUSTRY

  • Albert Einstein Healthcare Network

    lead OTHER

Principal Investigators

  • Darshak Karia, MD · Albert Einstein Medical Center. Albert Einstein Healthcare Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00804349 on ClinicalTrials.gov